Ono Pharmaceutical expands multi-target research collaboration with Congruence Therapeutics

United Therapeutics' ralinepag reduces risk of clinical worsening in pivotal PAH study

Genentech's fenebrutinib meets primary endpoint in pivotal Phase III study for multiple sclerosis

ValiRx establishes animal health subsidiary to target veterinary oncology market

FDA accepts rusfertide NDA and grants priority review for polycythemia vera

UAE approves PYRUKYND for treatment of thalassaemia

Sanofi's rilzabrutinib receives orphan drug designation in Japan for IgG4-related disease

Genflow Biosciences receives first EUR336,467 tranche of EUR4m Wallonia grant

Novacyt completes acquisition of Southern Cross Diagnostics

Eli Lilly's Olumiant (baricitinib) receives positive European regulatory opinion for approval to treat adolescents with severe alopecia areata

Atrium Therapeutics launches as newly independent, publicly traded company

Innovent Biologics' Jaypirca approved in China for new indication

Gemma Biotherapeutics doses first parent in GB221 Phase 1/2 CHARISMA clinical trial

Neurizon Therapeutics doses first participant in NUZ-001 Regimen I HEALEY ALS Platform Trial

Melodia Therapeutics reports award of US patent covering MLD-151